OBJECTIVE@#To detect
chromosomal aberrations by using cytoplasmic
light chain
immunofluorescence with fluorescence in situ hybridization (cIg-FISH), and to explore the correlation of del(17p13) with clinical characteristics,
drug response and
prognosis among
patients with newly diagnosed
multiple myeloma (NDMM).@*
METHODS @#Clinical data of 198 cases of NDMM was collected. cIg-FISH and a specific probe (TP53) were used to detect karyotypic
abnormalities in
bone marrow samples derived from the
patients . Correlation between karyotypic
abnormalities and clinical data was analyzed.@*RESULTS@#Nineteen of the 198
patients (9.6%) were found to have a
karyotype involving del(17p13). The overall
survival (OS) and
progression-free survival (PFS) for
patients with or without del(17p13) was significantly different (P<0.01). No significant difference was found in OS and PFS between
patients carrying a del(17p13) on
bortezomib and non-
bortezomib regimen (OS P = 0.873; PFS P = 0.610).@*CONCLUSION@#cIg-FISH is a simple and convenient
method for the
detection of karyotypic anomalies in
multiple myeloma . Del(17p13) is an
indicator for poor
prognosis for
multiple myeloma patients .
Bortezomib cannot improve the
survival disadvantage of del(17p13).